Original Articles

Li JL, Hayden MR, Almqvist EW, Brinkman RR, Durr A, Dode C, Morrison PJ, Suchowersky O, Ross CA, Margolis RL, Rosenblatt A, Gomez-Tortosa E, Cabrero DM, Novelletto A, Frontali M, Nance M, Trent RJ, McCusker E, Jones R, Paulsen JS, Harrison M, Zanko A, Abramson RK, Russ AL, Knowlton B, Djousse L, Mysore JS, Tariot S, Gusella MF, Wheeler VC, Atwood LD, Cupples LA, Saint-Hilaire M, Cha JH, Hersch SM, Koroshetz WJ, Gusella JF, MacDonald ME, Myers RH. A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum Genet 2003;73:682-687.
Yohrling GJ, IV, Jiang GC-T, DeJohn MM, Miller DW, Young AB, Vrana KE, Cha J-HJ. Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. Mol Brain Res 2003;119:28-36.
Luthi-Carter R, Apostol BL, Dunah AW, DeJohn MM, Farrell LA, Bates GP, Young AB, Standaert DG, Thompson LM, Cha J-HJ. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA expression levels, protein abundance, interacting proteins and phosphorylation. Neurobiol Dis 2003;14:624-636.
Yohrling GJ, Farrell, LA, Hollenberg AN, Cha J-HJ. Mutant huntingtin increases nuclear corepressor function and enhances ligand-dependent nuclear hormone receptor activation. Mol Cell Neurosci 2003;23:28-38.
Gomez-Isla T, Irizarry MC, Mariash A, Cheung B, Soto O, Schrump S, Sondel J, Kotilinek L, Day J, Schwarzschild MA, Cha J-HJ, Newell K, Miller DW, Uéda K, Young AB, Hyman BT, Ashe KH. Motor dysfunction and gliosis with preserved dopaminergic markers in human a-synuclein A30P transgenic mice. Neurobiol Aging 2003;24:245-258.
Yohrling GJ, IV, Jiang GC-T, DeJohn MM, Robertson DJ, Vrana KE, Cha J-HJ. Inhibition of tryptophan hydroxylase activity and decreased 5-HT 1A receptor binding in a mouse model of Huntington's disease. J Neurochem 2002;82:1-8.
Chan EYW, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha J-HJ, Aronin N, Hayden MR, Olson JM. Increased huntingtin protein length reduces the severity of polyglutamine-induced gene expression changes in mouse models of huntington disease. Hum Mol Genet 2002;11:1939-1951.
Cha J-HJ, Farrell LA, Ahmed SF, Frey A, Hsiao-Ashe KK, Young AB, Penney JB, Hyman BT, Irizarry MC. Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein, Neurobiol Dis 2001;8:90-102.
Chen M, Ona VO, Ferrante RHJ, Fink KB, Li M, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel J-P, Cha J-HJ, and Friedlander RM. Minocycline inhibits caspase-1 and capsase-3 expression and delays mortality in a transgenic mouse model of Huntington's disease, Nat Med 2000;6:797-801.
Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling S, Ross CA, Borchelt DR, Tapscott SJ, Young AB, Cha J-HJ, and Olson JM. Decreased expression of striatal signaling genes in a mouse model of Huntington’s disease, Hum Mol Genet 2000;9:1259-1271.
Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB Jr, Siemers E, Shoulson I, and the Huntington Study Group. Rate of functional decline in Huntington’s disease. Neurology 2000;54:452-458.
Kosinski CM, Cha J-H, Young AB, Davies SW, Bates GP, Schwarz M. Intranuclear inclusions in subtypes of striatal neurons in Huntington’s disease transgenic mice. NeuroReport 1999;10:3891-3896.
Kosinski CM, Cha J-H, Young AB, Schwarz M. Chorea Huntington: tiermodelle eröffnen neue Hypothesen zu Pathophysiologie und Therapie. Nervenarzt 1999;70:878-888.
Ona VO, Li M, Vonsattel JPG, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li X-J, Stieg PE, Yuan J, Penney JB, Young AB, Cha J-HJ, Friedlander RM. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington’s disease. Nature 1999;399:263-267.
Cha J-HJ, Frey AS, Alsdorf SA, Kerner JA, Kosinski CM, Mangiarini L, Penney JB Jr, Davies SW, Bates GP, Young AB. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington’s disease. Philos Trans R Soc Lond B 1999;354:981-989.
Kawamata T, Ren JM, Cha J-HJ, and Finklestein SP. Intracisternal antisense to growth-associated protein-43 (GAP-43) blocks the recovery-promoting effects of basic fibroblast growth factor (bFGF) after focal stroke. Exp Neurol 1999;158:89-96.
Cha J-HJ, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci (USA) 1998;95:6480-5.
Kosinski CM, Cha J-H, Young AB, Persichetti F, MacDonald M, Gusella JF, Penney Jr. JB, Standaert DG. Huntingtin immunoreactivity in the rat neostriatum: differential accumulation in projection and interneurons. Exp Neurol 1997;144:239-47.
Cha JJ, Dure IV LS. Trinucleotide repeats in neurological diseases: an hypothesis concerning the pathogenesis of Huntington's disease, Kennedy's disease, and spinocerebellar ataxia type I. Life Sci 1994;54:1459-64.
Cha J-HJ , Johnston MV. Rapid nonisotopic analysis of glutamate receptor gene expression using reverse transcriptase-polymerase chain reaction. J Receptor Res 1994;14:209-16.
Cha JJ, Kinsman SL, Johnston MV. RNA editing of a human glutamate receptor subunit. Mol Brain Res 1994;22:323-8.
MacDonald ME, Barnes G, Srinidhi J, Duyao MP, Ambrose CM, Myers RH, Gray J, Conneally PM, Young A, Penney J, Hollingsworth Z, Koroshetz W, Bird E, Vonsattel, JP, Bonilla E, Alvir J, Bickham Conde J, Cha J-H, Dure L, Gomez F, Ramos-Arroyo M, Sanchez-Ramos J, Snodgrass SR, de Young M, Wexler NS, Moscowitz C, Penchaszadeh G, Brzustowicz L, MacFarlane H, Anderson MA, Jenkins B, Gusella JF. Gametic but not somatic instability of CAG repeat length in Huntington’s disease. J Med Genet 1993;30:982-6.
Duyao MP, Ambrose CM, Myers RH, Novelletto A, Persichetti F, Frontali M, Folstein SE, Ross C, Franz ML, Abbott M, Gray J, Conneally PM, Young A, Penney J, Hollingsworth Z, Shoulson I, Lazzarini AM, Falek A, Koroshetz W, Sax DS, Bird E, Vonsattel J-P, Bonilla E, Alvir J, Bickham Conde J, Cha J-H, Dure L, Gomez F, Ramos M, Sanchez-Ramos J, Snodgrass SR, de Young M, Wexler NS, Moscowitz C, Penchaszadeh G, MacFarlane H, Anderson MA, Jenkins B, Srinidhi J, Barnes G, Gusella JF, MacDonald ME . Trinucleotide repeat length instability and age of onset in Huntington's Disease. Nature Genet 1993;4:387-92.
Cha JJ, Makowiec RL, Penney JB, Young AB. Multiple conformations of rat brain (RS)- a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors as revealed by quantitative autoradiography. Mol Pharmacol 1992;41:832-8.
Davis RE, Wilmot GR, Cha JJ. Glutamic acid-insensitive [ 3H]kainic acid binding in goldfish brain. Brain Res 1992;571:73-8.
Cha JJ, Dure IV LS, Sakurai SY, Penney JB, Young AB. 2,4,5-Trihydroxyphenylalanine (6-hydroxy-DOPA) displaces [ 3H]AMPA binding in rat striatum. Neurosci Lett 1991;132:55-8.
Makowiec RL, Cha JJ, Penney JB, Young AB. Characterization of cerebellar excitatory amino acid binding sites in normal, granuloprival, and purkinje cell deficient mice. Neuroscience 1991;42:671-81.
Makowiec RL, Albin RL, Cha JJ, Young AB, Gilman S. Two types of quisqualate receptors are decreased in human olivopontocerebellar atrophy cerebellar cortex. Brain Res 1990;523:309-12.
Cha JJ, Makowiec RL, Penney JB, Young AB. L-[ 3H]Glutamate labels the metabotropic excitatory amino acid receptor in rodent brain. Neurosci Lett 1990;113:78-83.
Nielsen EØ, Drejer J, Cha JJ, Young AB, Honoré T. Autoradiographic characterization of quisqualate binding sites in rat brain using the antagonist [ 3H]CNQX: comparison with [ 3H]AMPA binding sites. J Neurochem 1990;54:686-95.
Cha JJ, Hollingsworth ZR, Greenamyre JT, Young AB. Contamination of commercially available quisqualic acid by glutamic acid and aspartic acid. J Neurosci Methods 1989;27:143-8.
Nielsen EØ, Cha JJ, Honoré T, Penney JB, Young AB. Thiocyanate stabilizes AMPA binding to the quisqualate receptor. Eur J Pharmacol 1988;157:197-203.

Cha JJ, Greenamyre JT, Nielsen EØ, Penney JB, Young AB. Properties of quisqualate-sensitive L-[ 3H]glutamate binding sites in rat brain as determined by quantitative autoradiography. J Neurochem 1988;51:469-78.

Cha JJ, O’Brien DR, Dowling JE. Effects of D-aspartate on excitatory amino acid-induced release of [ 3H]GABA from goldfish retina. Brain Res 1986;376:140-8.

Proceedings of Meetings

Cha J-HJ, Huffard BH, Kerner JA, Mangiarini L, Davies SW, Bates GP, Young AB. Reduced metabotropic glutamate receptor expression in Huntington’s disease transgenic mouse brain. 17 th International Meeting of the World Federation of the Neurology Research Group on Huntington’s Disease, Sydney, Australia,1997.

Lichtenbaum RA, Talati A, Kerner JA, Young AB, Cha JJ. Antisense oligodeoxynucleotides directed against mGluR5 metabotropic glutamate receptor may protect against malonic acid lesions in rat striatum. Antisense Oligonucleotide Gene Knockout in the Nervous System, Oxford, England, 1997.

Cha JJ, Talati A, Kerner JA, Lichtenbaum RA, Young AB. Antisense oligodeoxynucleotides directed against mGluR5 metabotropic glutamate receptor protect against malonic acid lesions in rat striatum. Neuropharmacology 1996;35:A7.

Cha JJ, O’Brien DR, Dowling JE. Effects of D-aspartate on excitatory amino acid-induced release of ( 3H)-GABA from goldfish retina. Invest Ophthalmol Vis Sci Suppl 1984;25:86.

Reviews, Chapters, and Editorials

Leegwater-Kim J, Cha J-HJ. The Paradigm of Huntington’s Disease: Therapeutic Opportunities in Neurodegeneration. NeuroRx 2004;1:128-138.

Luthi-Carter R and Cha J-HJ. Mechanisms of Transcriptional Dysregulation in Huntington’s Disease. Clin Neurosci Res 2003;3:165-177.

Benn CL, Farrell LA, Cha J-HJ. Neurotransmitter Receptor Analysis in Transgenic Mouse Models In: Kohwi Y, ed. Triplet Repeat Protocols. Humana Press, in press.

Braveman MW, Chen-Plotkin AS, Yohrling GJ and Cha J-HJ. Chromatin Immunoprecipitation (ChIP) Technique for Study of Transcriptional Dysregulation in Intact Mouse Brain. In: Kohwi Y, ed. Triplet Repeat Protocols. Humana Press, in press.
Yohrling GJ and Cha J-HJ. Neurochemistry of Huntington’s Disease. In: Bates GP, Harper PS, and Jones AL, editors. Huntington’s Disease, 3 rd Edition. Oxford: Oxford University Press, 2002, p. 276-308.
Yohrling GJ and Cha J-HJ. Neuroprotection in Huntington’s Disease. In: Lo EH and Marwah J, editors. Neuroprotection: Basic and Clinical Aspects. Prominent Press, 2002, p. 641-659.
Cha J-HJ. Transcriptional dysregulation in Huntington’s disease. Trends Neurosci 2000;23:387-392.
Cha J-HJ, Young AB. Huntington’s Disease. In: Watson SJ, editor. Psychopharmacology: The Fourth Generation of Progress – Version No. 2, CD ROM. Lippincott Williams & Wilkins, 1999, http://www.acnp.org/citations/GN401000151/
Young AB, Cha J-HJ, Makowiec RL, Albin RL, Penney JB. The anatomy of non-N-methyl-D-aspartate excitatory amino acid binding sites in mammalian brain. In: Meldrum BS, Moroni F, Simon RP, and Woods JH, editors. Excitatory Amino Acids. New York: Raven Press, Ltd., 1991, p. 55-60.
Young AB, Maragos WF, Cha JJ, Penney JB. Distribution of PCP and glutamate receptors in normal and pathologic mammalian brain. In: Barnard EA, Costa E, editors. Allosteric Modulation of Amino Acid Receptors: Therapeutic Implications. New York: Raven Press, Ltd; 1989. p. 357-75.

Young AB, Penney JB, Cha JJ, Olson, JMM, Greenamyre JT, Albin RL, and Richfield EK. Neuronal and anatomical localization of excitatory amino acid receptor subtypes in vertebrate brain. In: Lehmann J, Turski LA, Cavalheiro EA, editors. Frontiers of Excitatory Amino Acid Research. New York: Alan R. Liss; 1988. p. 109-15.

Clinical Communications

Huntington Study Group. Minocycline Safety and Tolerability in Huntington's Disease. Neurology, in press.

Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, Marder K, Penchaszadeh G, Roberts SA, Gayan J, Brocklebank D, Cherny SS, Cardon LR, Gray J, Dlouhy SR, Wiktorski S, Hodes ME, Conneally PM, Penney JB, Gusella J, Cha JH, Irizarry M, Rosas D, Hersch S, Hollingsworth Z, MacDonald M, Young AB, Andresen JM, Housman DE, De Young MM, Bonilla E, Stillings T, Negrette A, Snodgrass SR, Martinez-Jaurrieta MD, Ramos-Arroyo MA, Bickham J, Ramos JS, Marshall F, Shoulson I, Rey GJ, Feigin A, Arnheim N, Acevedo-Cruz A, Acosta L, Alvir J, Fischbeck K, Thompson LM, Young A, Dure L, O'Brien CJ, Paulsen J, Brickman A, Krch D, Peery S, Hogarth P, Higgins DS, Jr., Landwehrmeyer B. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci (USA) 2004;101:3498-3503.

Singhal AB, Newstein MC, Budzik R, Cha JH, Rordorf G, Buonanno FS, Panzara MA. Diffusion-weighted magnetic resonance imaging abnormalities in Bartonella encephalopathy. J Neuroimaging 2003;13:79-82.

Sullivan FR, Bird ED, Alpay M, and Cha J-HJ. Remotivation therapy and Huntington’s disease: a path to better living. J Neurosci Nursing 2001;33:136-142.

Dissertation

Cha J-HJ. AMPA distinguishes multiple types of quisqualate binding sites in rat brain. The University of Michigan, 1991. (Chair: Young AB, Department: Neuroscience)